Loading...
XSWXSANN
Market cap116mUSD
Dec 23, Last price  
11.44CHF
1D
9.37%
1Q
28.25%
Jan 2017
-97.84%
IPO
-98.77%
Name

Santhera Pharmaceuticals Holding AG

Chart & Performance

D1W1MN
XSWX:SANN chart
P/E
1.92
P/S
1.01
EPS
5.97
Div Yield, %
0.00%
Shrs. gr., 5y
73.78%
Rev. gr., 5y
26.71%
Revenues
103m
+1,283.84%
781,0009,226,00048,0001,643,00020,609,0003,265,0003,538,0001,319,0002,591,0004,321,00019,033,00022,943,00031,657,00075,376,00015,008,000-1,595,0007,473,000103,414,000
Net income
55m
P
-28,258,000-27,871,000-44,656,00025,923,000-11,256,000-27,838,000-31,448,000-5,755,000-7,534,0005,949,000-35,415,000-51,532,000-54,186,000-18,973,000-67,659,000-55,526,000-71,076,00054,782,000
CFO
47m
P
-24,833,000-22,371,000-45,691,000-20,753,000-6,636,000-19,894,000-11,039,000-6,976,000-6,063,000-22,390,000-27,137,000-39,633,000-37,865,0002,595,000-43,510,000-37,359,000-29,843,00047,271,000
Earnings
Apr 23, 2025

Profile

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes vamorolone, which is being developed as treatments for Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises lonodelestat (POL6014) to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies. The company also out-licenses outside North America and France rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.
URL
https://www.santhera.com/
IPO date
Nov 03, 2006
Employees
45
Domiciled in
CH
Incorporated in
CH

Valuation

Title
CHF in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
103,414
1,283.84%
7,473
-568.53%
(1,595)
-110.63%
Cost of revenue
52,875
59,550
55,539
Unusual Expense (Income)
NOPBT
50,539
(52,077)
(57,134)
NOPBT Margin
48.87%
3,582.07%
Operating Taxes
38
460
809
Tax Rate
0.08%
NOPAT
50,501
(52,537)
(57,943)
Net income
54,782
-177.08%
(71,076)
28.00%
(55,526)
-17.93%
Dividends
Dividend yield
Proceeds from repurchase of equity
18,820
511
20,297
BB yield
Debt
Debt current
21,514
22,750
15,977
Long-term debt
641
22,917
28,811
Deferred revenue
16,808
Other long-term liabilities
5,336
36,311
30,008
Net debt
(8,639)
43,870
23,112
Cash flow
Cash from operating activities
47,271
(29,843)
(37,359)
CAPEX
(90)
(3,956)
(15)
Cash from investing activities
(18,044)
(3,932)
69
Cash from financing activities
(171)
13,993
46,022
FCF
27,328
(28,622)
(57,365)
Balance
Cash
30,370
1,353
21,208
Long term investments
424
444
468
Excess cash
25,623
1,423
21,756
Stockholders' equity
(571,457)
(624,708)
(501,817)
Invested Capital
658,285
661,217
592,671
ROIC
7.65%
ROCE
58.21%
EV
Common stock shares outstanding
10,924
6,093
3,417
Price
Market cap
EV
EBITDA
53,583
(42,219)
(53,410)
EV/EBITDA
Interest
21,314
20,189
16,423
Interest/NOPBT
42.17%